Impact of Text Messages to Promote Secondary Prevention After Acute Coronary Syndrome (IMPACS)
Impact of a Mobile Phone Text Messages Intervention on the Secondary Prevention of Cardiovascular Events After Acute Coronary Syndrome
調査の概要
詳細な説明
Purpose of the trial: The purpose of the study is to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention after acute coronary syndrome hospitalization.
Trial design: Two-parallel arm, single-blind, block randomization.
Primary endpoint: The proportion achieving guideline levels of modifiable risk factors (LDL-C <70mg/dL, blood pressure <140/90 mm Hg, exercising regularly [≥5 d/wk × 30minutes of moderate exercise per session], nonsmoker status, and BMI <25). The investigators prespecified in the statistical analysis plan the efficacy variable of proportion achieving combined risk factor control (achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed above) as a measure of a multiple risk factor effect.
Secondary endpoints: The plasma LDL-C level at 6 months, Level of physical activity, Blood Pressure, Medication adherence measured via Morisky scale, Proportion of non-smokers, Body mass index (BMI), Rates death and hospitalization up to 6 months.
Duration of follow-up: 6 months
Trial treatment:
Intervention: The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order.
Control: The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. The participants will also receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Expected sample size, enrollment and expected number of centers:
Sample size = 160 Recruitment start date: November, 2017 Recruitment end date: May, 2019 Follow-up end date: November, 2019 Number of centers: 1
Statistical considerations:
- Intention to treat analysis
- The trial has >90% power (2 sided alpha = 0.05) to detect 15% difference in achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed.
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究場所
-
-
MG
-
Belo Horizonte、MG、ブラジル、30575210
- 募集
- Luiz Guilherme Passaglia
-
コンタクト:
- Luiz G Passaglia, master's
- 電話番号:3199038674
- メール:lg.passaglia@uol.com.br
-
主任研究者:
- Luiz G Passaglia, M.D.
-
主任研究者:
- Antônio LP Ribeiro, M.D., Ph.D
-
副調査官:
- Luisa CC Brant, M.D., Ph.D
-
副調査官:
- Bruno R Nascimento, M.D., Ph.D.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Consecutive patients who have been hospitalized at the UFMG's University Hospital with primary or secondary diagnosis of Acute Coronary Syndrome and are discharged for outpatient follow-up;
- Age ≥ 18 years, of both sexes;
- Patients who are able to receive text messages by their own mobile phone.
Exclusion Criteria:
- Refusal or inability to sign the Informed Consent.
- Complete illiteracy.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Experimental
Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
|
The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention.
The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts.
There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients.
Texts will be sent out 4 times per week for 180 days.
All participants in the same stream will receive the same texts in the same order.
The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome.
They will also receive simple and short text messages related to the importance of trial participation.
|
|
介入なし:No Intervention
Usual Care
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Escore of combined risk factor control
時間枠:6 months
|
The proportion achieving guideline levels of modifiable risk factors (LDL-C <77mg/dL, blood pressure <140/90 mm Hg, exercising regularly [≥5 d/wk × 30minutes of moderate exercise per session], nonsmoker status, and BMI <25).
We prespecified in the statistical analysis plan the efficacy variable of proportion achieving combined risk factor control (achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed above) as a measure of a multiple risk factor effect
|
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Plasma LDL-C level
時間枠:6 months
|
Fasting blood sample
|
6 months
|
|
Level of physical activity (measured via
時間枠:6 months
|
Measured by research blinded to treatment allocation - The level of physical activity will be mensured by the International Physical Activity Questionnaire Short Form (IPAQ-SF) and it will be validated in one-fifth of the participants by using accelerometers
|
6 months
|
|
Blood Pressure
時間枠:6 months
|
Measured by research blinded to treatment allocation - 3 resting, sitting digital recordings, mean of last 2 readings
|
6 months
|
|
Proportion of non-smokers
時間枠:6 months
|
Measured by research blinded to treatment allocation - Self-reported smoking / quitting attempts will be confirmed with a Carbon Monoxide Meter Breath Test
|
6 months
|
|
Body mass index (BMI)
時間枠:6 months
|
Measured by research blinded to treatment allocation
|
6 months
|
|
Medication adherence (measured via "Medida de adesão aos tratamentos" - MAT)
時間枠:6 months
|
Measured by research blinded to treatment allocation It is an instrument composed of seven items that evaluate the behavior of the individual in relation to daily use of medicines.
The answers are obtained by means of a six-point ordinal scale that varies from always (1) to never (6).
The values obtained with the answers to the seven items are summed and divided by the number of items (values vary from 1 to 6).
Subsequently, values 5 and 6 are computed as one (adherent) and the others are computed as zero (non-adherent).
|
6 months
|
|
Death from any cause
時間枠:6 months
|
Medical records and database
|
6 months
|
|
Rehospitalization
時間枠:6 months
|
Self-report, medical records and database
|
6 months
|
|
Cardiovascular death
時間枠:6 months
|
Medical records and database
|
6 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
循環器疾患の臨床試験
-
HuidaGene Therapeutics Co., Ltd.募集
-
Hemab ApSPSI CRO募集フォン・ヴィレブランド病(VWD) | フォン・ヴィレブランド病 (VWD)、タイプ 1 | フォンウィルブランド病(VWD)、タイプ2 | Von Willebrand Disease(VWD)、タイプ3 | フォン・ウィルブランド病、タイプ2a | Von Willebrand病、タイプ2M | Von Willebrand病、タイプ2Nアメリカ, イギリス, オーストラリア
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ